Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Fei Shen
AddedFeb 15, 2024
UpdatedMay 31, 2026
Fei Shen

Fei Shen

Board Member, ArrePath

CrunchbaseLinkedInThe Org

Fei Shen's Career

ArrePath
ArrePath

Princeton, FL, US

Board Member· Board
Rgenta Therapeutics
Rgenta Therapeutics

Woburn, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Fei Shen's Career

ArrePath
ArrePath
Seed$20M162022Princeton, FL, US
Board Member· Board

Leadership at ArrePath

Lloyd J. PayneLloyd J. PayneCEO
Venkat SrinivasanVenkat SrinivasanBoard Member
Dylan MorrisDylan MorrisBoard Member

Similar to ArrePath

AMPLY DiscoveryAMPLY DiscoveryBelfast, Belfast District, GBDrug Discoveryest. 2021AMPLY DiscoveryBelfast, Belfast District, GB · est. 2021

AMPLY Discovery: Innovating anti-infective health solutions for human and animal wellbeing.

Seed · $920k8
Regenerative BioRegenerative BioCambridge, MA, USPharmaceuticalsest. 2020Regenerative BioCambridge, MA, US · est. 2020

Regenerative Bio: AI-driven biotech firm pioneering anti-aging solutions through pharmaceutical tech.

Angel · $10M13
Pathos AIPathos AIChicago, IL, USDrug Discoveryest. 2020Pathos AIChicago, IL, US · est. 2020

Pathos: AI and big data-driven platform streamlining end-to-end drug discovery and development.

Series B · $20M3
Flightpath BiosciencesFlightpath BiosciencesBerkeley, CA, USAntibiotic Therapies, Drug Deliveryest. 2019Flightpath BiosciencesBerkeley, CA, US · est. 2019

Flightpath Biosciences accelerates drug discovery and delivery, enhancing safety and reducing antibiotic resistance.

Series A · $1.1M8
Rgenta Therapeutics
Rgenta Therapeutics
Series A$116.9M352018Woburn, MA, US
Board Member· Board

Leadership at Rgenta Therapeutics

Martin HeideckerMartin HeideckerBoard Member
Travis WagerTravis WagerCo-Founder
Zhiping WengZhiping WengCo-Founder
Simon XiSimon XiCo-Founder

Fei Shen's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Fei Shen

Ghen MaynardGhen MaynardBoard Member · ArreoJulia LeJulia LeBoard Member · ArreoAnnie PearlAnnie PearlBoard Member · WorkRampNancy M. LeeNancy M. LeeBoard Member · ArrcusDan AhrensDan AhrensBoard Member · Arc